Abstract
No public abstract is available from the verified source records.
Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureArati V. Rao, David Alan Rizzieri, Carlos M. DeCastro, Louis F. Diehl, Anand Shreeram Lagoo, Joseph O. Moore, Jon P. Gockerman
Abstract
Authors
Institutions
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Global cancer statistics
10.3322/caac.20107 · 2011
Management of acute myeloid leukemia in elderly patients
10.1200/jco.1999.17.11.3569 · 1999
Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461)
10.1182/blood-2002-03-0772 · 2002
Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study
10.1182/blood.v89.9.3323 · 1997
Double induction strategy for acute myeloid leukemia: the effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: a randomized trial by the German AML Cooperative Group
1999
10.1038/sj.leu.2401445
10.1038/sj.leu.2401445 · 1999
Intensified induction chemotherapy with high dose cytarabine and etoposide for acute myeloid leukemia: a review and updated results of the Australian Leukemia Study Group
10.3109/10428199809092687 · 1998
High-dose cytarabine induction is well tolerated and active in patients with de novo acute myeloid leukemia older than 60 years
Provenance
crossref
Confidence 100%
openalex
Confidence 95%
unpaywall
Confidence 95%
datacite
Confidence 0%
10.1002/cncr.26290 · 2012
Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse
10.1200/jco.2001.19.13.3244 · 2001
High dose cytarabine plus gemtuzumab ozogamicin for patients with relapsed or refractory acute myeloid leukemia: Cancer and Leukemia Group B study 19902
10.1016/j.leukres.2010.07.017 · 2011
Is there a role for postremission therapy in older adults with acute myelogenous leukemia (AML)?
10.1038/sj.leu.2403827 · 2005
Unresolved referenced work
Kept as external metadata until matched
Design and analysis of phase I clinical trials
10.2307/2531693 · 1989
Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia
10.1200/jco.2003.04.036 · 2003
Preliminary report of the safety and efficacy of gemtuzumab ozogamicin (Mylotarg) given in combination with cytarabine and daunorubicin in patients with acute myeloid leukemia
2001
Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation
10.1182/blood-2003-01-0255 · 2003
Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence
10.1002/cncr.21326 · 2005
High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study of the alfa group
10.1038/sj.leu.2404434 · 2007
Gemtuzumab ozogamicin for relapsed and refractory acute myeloid leukemia and myeloid sarcomas
10.1080/1042819042000219485 · 2004
10.1111/j.1365-2141.2010.08095.x
10.1111/j.1365-2141.2010.08095.x · 2010
10.1038/sj.leu.2403901
10.1038/sj.leu.2403901 · 2005
Phase II pilot trial of gemtuzumab ozogamicin (GO) as first line therapy in acute myeloid leukemia patients age 65 or older
10.1016/j.leukres.2004.04.011 · 2005
Long-term disease-free survival after gemtuzumab, intermediate-dose cytarabine, and mitoxantrone in patients with CD33(+) primary resistant or relapsed acute myeloid leukemia
10.1200/jco.2007.15.9764 · 2008
Gemtuzumab ozogamicin, fludarabine, cytarabine and cyclosporine combination regimen in patients with CD33+ primary resistant or relapsed acute myeloid leukemia
10.1016/s0145-2126(03)00022-5 · 2003
Failure of three novel regimens to improve outcome for patients with relapsed or refractory acute myeloid leukaemia: a report from the Eastern Cooperative Oncology Group
10.1111/j.1365-2141.2009.07917.x · 2010
Identification of patients with acute myeloblastic leukaemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial
10.1200/jco.2010.31.4310 · 2011
10.1093/annonc/mdr346
10.1093/annonc/mdr346
10.1182/blood.v114.22.790.790
10.1182/blood.v114.22.790.790 · 2009
Gemtuzumab ozogamicin with or without interleukin 11 in patients 65 years of age or older with untreated acute myeloid leukemia and high-risk myelodysplastic syndrome: comparison with idarubicin plus continuous-infusion, high-dose cytosine arabinoside
10.1182/blood.v99.12.4343 · 2002
Gemtuzumab-ozogamicin in combination with fludarabine, cytarabine, idarubicin (FLAI-GO) as induction therapy in CD33-positive AML patients younger than 65 years
10.1016/j.leukres.2008.05.011 · 2008
Gemtuzumab ozogamicin in combination with attenuated doses of standard induction chemotherapy can successfully induce complete remission without increasing toxicity in patients with acute myeloid leukemia aged 55 or older
10.1111/j.1600-0609.2007.00946.x · 2007
A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia
10.1182/blood-2003-05-1620 · 2003
Gemtuzumab, fludarabine, cytarabine, and cyclosporine in patients with newly diagnosed acute myelogenous leukemia or high-risk myelodysplastic syndromes
10.1002/cncr.11239 · 2003
Sequential administration of gemtuzumab ozogamicin and conventional chemotherapy as first line therapy in elderly patients with acute myeloid leukemia: a phase II study (AML-15) of the EORTC and GIMEMA leukemia groups
2004
10.1111/j.1365-2141.2007.06646.x
10.1111/j.1365-2141.2007.06646.x · 2007
Unresolved referenced work
2011
Nucleoside analogues: mechanisms of drug resistance and reversal strategies
10.1038/sj.leu.2402114 · 2001
Comparison of antineoplastic activity of 2',2'-difluorodeoxycytidine and cytosine arabinoside against human myeloid and lymphoid leukemic cells
10.1097/00001813-199102000-00007 · 1991
Comparison of the induction of apoptosis in human leukemic cell lines by 2',2'-difluorodeoxycytidine (gemcitabine) and cytosine arabinoside
10.1016/0145-2126(95)00067-4 · 1995
Phase I evaluation of prolonged-infusion gemcitabine with irinotecan for relapsed or refractory leukemia or lymphoma
10.1200/jco.2002.08.166 · 2002
Age-specific differences in oncogenic pathway dysregulation and anthracycline sensitivity in patients with acute myeloid leukemia
10.1200/jco.2009.22.2547 · doi-reference
Phase I evaluation of gemcitabine, mitoxantrone, and their effect on plasma disposition of fludarabine in patients with relapsed or refractory acute myeloid leukemia
10.1080/10428190802210700 · doi-reference